Phenytoin-based Bivalent Ligands
2115
Kaminski, K., Rzepka, S., and Obniska, J., Synthesis and
anticonvulsant activity of new 1-[2-oxo-2-(4-phenylpipera-
zin-1-yl)ethyl]pyrrolidine-2,5-diones. Bioorg. Med. Chem.
Lett., 21, 5800-5803 (2011).
Kitano, Y., Usui, C., Takasuna, K., Hirohashi, M., and
Nomura, M., Increasing-current electroshock seizure test:
A new method for assessment of anti- and pro-convulsant
(
4b, 5e, 7c) exhibited 100% protection against scPTZ-
induced seizures. On the other hand, compound 5d
displayed more potent anticonvulsant activity than
the standard drug in the MES screen. In addition,
most of the compounds showed low neurotoxic proper-
ties in the neurotoxicity screen. The compound 5e ex-
hibited potent anticonvulsant properties in both test-
ed models with low neurotoxicity, therefore, can be re-
garded as a strong candidate for future investigations.
In addition, the majority of the pharmacologically active
test compounds did not violated Lipinski parameters,
and thus may possess good intestinal absorption and
can penetrate the blood brain barrier.
activities of drugs in mice. J. Pharmacol. Toxicol. Methods
,
35, 25-29 (1996).
Krall, R. L., Penry, J. K., White, B. G., Kupferberg, H. J., and
Swinyard, E. A., Antiepileptic drug development: II. Anti-
convulsant drug screening. Epilepsia, 19, 409-428 (1998).
Lenkowski, P. W., Batts, T. W., Smith, M. D., Ko, S. H.,
Jones, P. J., Taylor, C. H., McCusker, A. K., Davis, G. C.,
Hartmann, H. A., White, H. S., Brown, M. L., and Patel,
M. K., A pharmacophore derived phenytoin analogue with
increased affinity for slow inactivated sodium channels
exhibits a desired anticonvulsant profile. Neurophar-
macology, 52, 1044-1054 (2007).
Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P.
J., Experimental and computational approaches to esti-
mate solubility and permeability in drug discovery and
development settings. Adv. Drug Deliv. Rev., 46, 3-26 (2001).
Löscher, W., Nau, H., Marescaux, C., and Vergnes, M., Com-
parative evaluation of anticonvulsant and toxic potencies
of valproic acid and 2-en-valproic acid in different animal
models of epilepsy. Eur. J. Pharmacol., 99, 211-218 (1984).
Löscher, W., Honack, D., Fassbender, C. P., and Nolting, B.,
The role of technical, biological and pharmacological factors
in the laboratory evaluation of anticonvulsant drugs, III:
Pentylenetetrazole seizure models. Epilepsy Res., 8, 171-
189 (1991).
ACKNOWLEDGEMENTS
The authors are grateful to Dr. Wafaa El-Eraky,
Associate Professor of Pharmacology and Toxicology
Department, National Research Center, Cairo. Egypt
for carrying out the biological testing.
REFERENCES
Ahsan, M. J., Samy, J. G., Khalilullah, H., Nomani, M. S.,
Saraswat, P., Gaur, R., and Singh, A., Molecular proper-
ties prediction and synthesis of novel 1,3,4-oxadiazole
analogues as potential antimicrobial agents. Bioorg. Med.
Chem. Lett., 21, 7246-7250 (2011).
Cramer, J. A., Mintzer, S., Wheless, J., and Mattson, R. H.,
Adverse effects of antiepileptic drugs: a brief overview of
important issues. Expert Rev. Neurother., 10, 885-891
(2010).
Cuadrado, A. and Armijo, J. A., Beneficial interactions between
vigabatrin and valproate against seizures induced by
pentylenetetrazole in mice. Pharmacol. Res., 51, 489-496
(2005).
Löscher, W., New visions in the pharmacology of anticonvul-
sion. Eur. J. Pharmacol., 342, 1-13 (1998).
Löscher, W. and Schmidt, D., New horizons in the develop-
ment of antiepileptic drugs: Innovative strategies. Epilepsy
Res., 69, 183-272 (2006).
Obniska, J., Kaminski, K., Dorota, S., and Pichor, J., Syn-
thesis and anticonvulsant activity of new N-[(4-arylpiper-
azin-1-yl)-alkyl] derivatives of 3-phenyl-pyrrolidine-2,5-
dione. Eur. J. Med. Chem., 44, 2224-2233 (2009).
Ouchi, M., Inoue, Y., Liu, Y., Nagamune, S., Nakamura, S.,
Wada, K., and Hakushi, T., Convenient and efficient
tosylation of oligoethylene glycosl and the related alcohols
in tetrahydrofuran-water in the presence of sodium
hydroxide. Bull. Chem. Soc. Jpn., 63, 1260-1262 (1990).
Pandeya, S. N., Yogeeswari, P., and Stables, J. P., Synthesis
and anticonvulsant activity of 4-bromophenyl substituted
aryl semicarbazones. Eur. J. Med. Chem., 35, 879-886
(2000).
Dimmock, J. R., Pandeya, S. N., Quail, J. W., Allen, T. M.,
and Kao, G. Y., Evaluation of the semicarbazones, thio-
semicarbazones and bis-carbohydrazones of some aryl ali-
cycylic ketones for anticonvulsant and other biological
properties. Eur. J. Med. Chem., 30, 303-314 (1995).
Fisher, R. S., Animal models of the epilepsies. Brain Res.
Rev., 14, 245-278 (1989).
George, S. R., O’Dowd, B., and Lee, S. P., G-protein-coupled
receptor oligomerization and its potential for drug discov-
ery. Nat. Rev. Drug Discov., 1, 808-820 (2002).
Greenwood, R. S., Adverse effects of antiepileptic drugs.
Epilepsia, 41, 42-52 (2000).
Huber, D., Löber, S., Hübner, H., and Gmeiner, P., Bivalent
molecular probes for dopamine D2-like receptors. Bioorg.
Med. Chem., 20, 455-466 (2012).
Paxton, J. W., Rowell, F. J., and Ratcliffe, J. G., Production
and characterisation of antisera to diphenylhydantoin
suitable for radioimmunoassay. J. Immunol. Methods, 10,
Hudkins, R. L. and DeHaven-Hudkins, D. L., Phenytoin
317-327 (1976).
Poupaert, J. H., Mergen, F., and Lerot, T., Synthesis of
bivalent ligands derived from phenytoin. Bull. Soc. Chim.
derivatives as potent
4, 2185-2188 (1994).
σ-ligands. Bioorg. Med. Chem. Lett.,